Business Context and Reporting Period
Mangoceuticals, Inc. (MGRX), a Texas corporation listed on the Nasdaq Capital Market, filed this Form 8-K on February 6, 2026, regarding an event dated February 4, 2026. The filing addresses a regulatory deficiency notification received from Nasdaq.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance triggering the deficiency: the common stock bid price closed below $1.00 per share for 30 consecutive business days prior to February 4, 2026.
Material Changes
The material change reported is the Company's failure to satisfy Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. This status change resulted in a formal deficiency notification from the Listing Qualifications Staff of Nasdaq.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has a 180-calendar day period, ending August 3, 2026, to regain compliance.
- Remediation Requirement: To cure the deficiency, the bid price must close at $1.00 per share or more for a minimum of 10 consecutive business days.
- Current Status: The notice has no immediate effect on the listing or trading of the Company's common stock.
- Management Action: Management intends to actively monitor the closing bid price and will consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current trading price of MGRX to assess proximity to the $1.00 threshold.
- Monitor subsequent filings for any reverse stock split proposals or other capital structure changes intended to address the bid price deficiency.
- Confirm the Company's cash position and liquidity in its most recent 10-Q or 10-K to evaluate its ability to sustain operations while addressing the listing issue.
- Track the stock's daily closing prices to determine if the 10-day compliance window is being met within the 180-day period.